NFKB1 and non-small cell lung carcinoma: The expression levels of these marker genes, which govern NF-κB activities, were affected by GRA16, but not by irinotecan in NSCLC cells, suggesting that GRA16 prevents the development of drug resistance (Figure 5G,H).